Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
Changhua site meets international regulatory standards for global medical applications
Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation in adults
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Dilip Shanghvi to continue as the Executive Chairman of the Board
Subscribe To Our Newsletter & Stay Updated
